Our CEO, Craig Thompson, recently shared his insights during a panel at the #FierceBiotechSummit, where he discussed the future of #neuroscience innovation. We’re grateful for the opportunity to be a part of this important discussion. Learn more: https://lnkd.in/egyxTVTT
About us
Cerevance
- Website
-
http://www.cerevance.com
External link for Cerevance
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
One Marina Park Drive
Suite 1410
Boston, MA 02210, US
-
418 CAMBRIDGE SCIENCE PARK MILTON ROAD
CAMBRIDGE, CB4 0PZ, GB
Employees at Cerevance
-
Keith Page
-
Marina Lizio
Principal bioinformatician CNS and -Omics, based in Cambridge,UK.
-
Damon McCune, PhD, RDN, LD
Medical Affairs leader steering business excellence through innovation, empowerment, and strategy.
-
Matthias Kleinz
Life Science Investor and Executive Vice President at UPMC Enterprises
Updates
-
We've achieved our second milestone in our research collaboration with Merck and are excited by the advancements we’ve made in identifying potential novel therapeutic targets for patients with Alzheimer’s disease. A huge thank you to our dedicated team and partners at Merck for their hard work and commitment to excellence. Read the press release here: https://lnkd.in/eFFxkMgH
-
Our CEO, Craig Thompson, will be joining a panel at the upcoming #FierceBiotechSummit to discuss the latest in CNS drug discovery. https://lnkd.in/e2z9xrQ2
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
globenewswire.com
-
What an inspiring and important story! Watch the latest episode of Bottom Line on BCTV to learn more about the impact of Parkinson's disease and the significant unmet treatment needs of those affected. The Cerevance team is committed to developing novel therapies for individuals with PD, and stories like this fuel our dedication to driving innovation and making a positive impact on patients. https://lnkd.in/e-4hJepP
Bottom Line Parkinsons Discussion 8 12 24
https://www.youtube.com/
-
We are thrilled to welcome Dr. Sagar Vaidya, M.D., Ph.D., as our new Chief Medical Officer! In combination with a distinguished track record in advancing innovative therapeutic programs, Dr. Vaidya’s deep expertise in drug discovery and clinical research will support our mission of developing next-generation treatments to improve the lives of individuals with CNS disorders. To learn more about Dr. Vaidya and our novel approach to CNS therapies, read here: https://lnkd.in/ex44Fjzd
Cerevance Appoints Sagar Vaidya, M.D. Ph.D., as Chief Medical Officer
globenewswire.com
-
Summer spirit is in full swing at Cerevance! Our UK company-wide summer party was a fantastic celebration of our team's hard work and dedication. From breakthrough research in CNS disorders to incredible team achievements, there's much to be proud of. To learn more about our mission, visit https://lnkd.in/evtQMP9g
-
Interested in learning more about our precision approach for developing CNS treatments? Check out this recent article in PharmaVoice where our CEO Craig Thompson discusses how we leverage one of the largest in-house samples of human brain tissue to develop novel therapies for patients suffering from diseases like Parkinson’s and Alzheimer’s. https://lnkd.in/ezsHJVND
Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
pharmavoice.com
-
What’s next in #biotech? Join us at Fierce's #FierceBiotechSummit this September and gain insights from industry leaders, including our CEO Craig Thompson. https://lnkd.in/eVfgTXAd
FierceBiotech Summit
fiercebiotechsummit.com